Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections, finds a study published today in eLife.
Malaria infections can be devastating for pregnant mothers, particularly during their first pregnancies. If malaria parasites invade the placenta, they can starve babies of nutrition, potentially causing low birth weight, preterm deliveries, stillbirths, and pregnancy loss. But not all women are susceptible to placental malaria infections, and the new study may help clinicians to identify those at risk and researchers to develop new therapies to protect pregnant women from malaria and related complications.
A protein made by malaria parasites called VAR2CSA allows them to attach to placental cells and invade the placenta. "Many women produce antibodies that can prevent this infection, and even those who have placental malaria during their first pregnancy are less likely to become infected during subsequent pregnancies because they have already developed protective antibodies," explains co-first author Dr Elizabeth Aitken, Research Officer at the Doherty Institute, University of Melbourne, Australia. "We set out to identify the features of these antibodies that help protect women from placental infections."
In their experiments, the research team used a machine learning technique to identify naturally acquired antibody features mid pregnancy that were associated with protection from placental malaria at delivery. They analysed 169 antibody features in 77 pregnant women from Madang, Papua New Guinea.
Of these features, they identified six that were associated with placental malaria protection. These fell into two broad groups: those related to preventing the parasites from binding to placental cells, and those that led to the destruction of infected blood cells. "Using these features, we created a model that could predict which pregnant women would develop placental malaria infections with 86% accuracy," says co-first author Timon Damelang, a PhD student at the Doherty Institute.
"These results suggest it is likely there are multiple pathways to protection against placental malaria," adds co-first author Amaya Ortga-Pajares, also a PhD student at the Doherty Institute.
"It will be interesting to learn whether this same combination of features can protect pregnant women from placental malaria infections in other populations," concludes senior author Professor Stephen Rogerson, Head of the Malaria Laboratory at the Doherty Institute, University of Melbourne. "This new insight is important for the development of novel vaccines or other treatments to protect pregnant women and their babies from the effects of malaria."
Emily Packer, Media Relations Manager
+44 (0)1223 855373
Catherine Somerville, Senior Media and Communications Officer
The Peter Doherty Institute for Infection and Immunity (Doherty Institute)
+61 422 043 498
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Immunology and Inflammation, while exploring creative new ways to improve how research is assessed and published. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest Immunology and Inflammation research published in eLife, visit https://elifesciences.org/subjects/immunology-inflammation.
About the Peter Doherty Institute for Infection and Immunity
Finding solutions to prevent, treat and cure infectious diseases and understanding the complexities of the immune system requires innovative approaches and concentrated effort. This is why The University of Melbourne - a world leader in education, teaching and research excellence - and The Royal Melbourne Hospital - an internationally renowned institution providing outstanding care, treatment and medical research - have partnered to create the Peter Doherty Institute for Infection and Immunity (Doherty Institute); a centre of excellence where leading scientists and clinicians collaborate to improve human health globally.